The treatment paradigm for thyroid cancer has shifted from a one-size-fits-all approach to
more personalized protocols that range from active surveillance to total thyroidectomy …

Context Low-risk differentiated thyroid cancer (DTC) is overdiagnosed, but true incidence
has increased as well. Owing to its excellent prognosis with low morbidity and mortality …

The clinical and epidemiological profiles of differentiated thyroid cancers (DTCs) have
changed in the last three decades. Today's DTCs are more likely to be small, localized …

The aim of post-surgical follow-up for differentiated thyroid carcinoma is the early
identification of the small proportion of patients who have residual disease or develop a …

The primary goal in the follow up of thyroid cancer patients is to identify and treat persistent
and recurrent disease at a time that minimizes morbidity and disease specific mortality. This …

Objective Because differentiated (follicular and papillary) thyroid cancer (DTC) may recur
years after initial treatment, the follow-up of patients with DTC is long term. However, this …

The last 10 years have seen a major paradigm shift in the management of thyroid cancer,
with greater reliance on serum thyroglobulin and neck ultrasonography, and less emphasis …

As differentiated (follicular and papillary) thyroid cancer (DTC) may recur years after initial
treatment, follow-up of patients with DTC is long term. However, this population has …

Although differentiated thyroid cancer (DTC) is typically an indolent disease with a high rate
of cure, recurrence is common (15%–30% of patients), even in early-stage disease. These …

Well-differentiated (follicular and papillary) thyroid carcinoma accounts for 80% to 90% of
the approximately 28,000 new cases each year and the estimated 376,000 existing cases of …